ArticleBMC gastroenterology2025
Disease detected through screening is associated with superior survival outcomes in stage III colorectal cancer: a retrospective study in a Chinese high-volume cancer center.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Healthcare providers' perspectives on implementing a primary care-based initiative to increase equitable bowel cancer screening participation in Australia.Health promotion international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeColorectal cancer (CRC) screening reduces CRC mortality through early detection of cancer while decreasing incidence via removal of precancerous lesions (adenomas). Moreover, screening is associated with a reduction in mortality through detection of CRC in early stage. Yet it is unclear whether screening decrease mortality in locally advanced CRC. This study aims to investigate the pathological characteristics and survival outcomes of stage III CRC patients detected through screening. Notably in China and most developing countries where opportunistic screening predominates, understanding the stage-specific survival benefits could inform national screening policy optimization.
methodsThis study involves a retrospective review of a cohort comprising 18,800 patients in Fudan University Shanghai Cancer Center, and a total of 4104 met the inclusion criteria. Propensity score matching (PSM) was conducted at a 1:4 ratio.
resultsCompared with cancers not detected through screening (n = 3967, 96.7%), cancers detected through screening (n = 137, 3.3%) were more likely to be older, to have colon cancer, vascular invasion, perineural invasion, smaller tumors or to receive radical surgery without neoadjuvant therapy. After PSM, cancer detection by screening was associated with better overall survival (OS) and a non-significant trend toward improved disease-free survival (DFS) in stage III CRC (5-year OS: 83.4% vs. 69.7%, P = 0.005; 3-year DFS: 75.6% vs. 70.3%, P = 0.064). Multivariate Cox analysis demonstrated that cancer detection by screening was an independently protective factor for OS (HR: 0.517, 95% CI: 0.341–0.782, P = 0.002) and DFS (HR: 0.683, 95% CI: 0.475–0.982, P = 0.040) in stage III patients.
conclusionThe study demonstrates that screening-detected cancers reduce mortality and recurrence risks among stage III CRC patients. These findings emphasize that screening improves survival outcomes not only through early-stage detection, and highlight the urgent need to increase screening coverage. The results support incorporating survival metrics into cost-effectiveness evaluations of screening programs, providing policymakers with more nuanced evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.